Clinical manifestations and immune response to tuberculosis

World J Microbiol Biotechnol. 2023 May 24;39(8):206. doi: 10.1007/s11274-023-03636-x.

Abstract

Tuberculosis is a far-reaching, high-impact disease. It is among the top ten causes of death worldwide caused by a single infectious agent; 1.6 million tuberculosis-related deaths were reported in 2021 and it has been estimated that a third of the world's population are carriers of the tuberculosis bacillus but do not develop active disease. Several authors have attributed this to hosts' differential immune response in which cellular and humoral components are involved, along with cytokines and chemokines. Ascertaining the relationship between TB development's clinical manifestations and an immune response should increase understanding of tuberculosis pathophysiological and immunological mechanisms and correlating such material with protection against Mycobacterium tuberculosis. Tuberculosis continues to be a major public health problem globally. Mortality rates have not decreased significantly; rather, they are increasing. This review has thus been aimed at deepening knowledge regarding tuberculosis by examining published material related to an immune response against Mycobacterium tuberculosis, mycobacterial evasion mechanisms regarding such response and the relationship between pulmonary and extrapulmonary clinical manifestations induced by this bacterium which are related to inflammation associated with tuberculosis dissemination through different routes.

Keywords: Clinical manifestations; Immune response; Mycobacterium tuberculosis; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Cytokines
  • Humans
  • Inflammation
  • Mycobacterium tuberculosis*
  • Public Health
  • Tuberculosis*

Substances

  • Cytokines